Significance and limits of cerebrospinal fluid beta-2-microglobulin measurement in course of acute lymphoblastic leukemia

P. Musto, P. Tomasi, N. Cascavilla, S. Ladogana, A. La Sala, L. Melillo, M. Nobile, G. Castoldi, M. Carotenuto

Research output: Contribution to journalArticle

Abstract

Cerebrospinal fluid beta-2-microglobulin (CSF-β2m) was measured longitudinally in 48 patients affected by acute lymphoblastic leukemia (ALL). Thirteen developed a central nervous system (CNS) involvement during the course of the disease; although moderately higher mean CSF-β2m levels were found in these subjects, no significant statistical differences were observed in comparison with patients without this complication and compared with the control group. No correlations were found between β2m and other biochemical parameters in CSF. Furthermore, CSF-β2m levels appeared to be influenced by previous combined chemoradiotherapeutic treatment for CNS prophylaxis, presence of meningeal non-neoplastic infiltrates, patients' ages, amount of CSF blasts, and their immunological phenotype. In particular, only clearly B-committed leukemic cells, when tested, showed a strong surface expression of β2m, as demonstrated by immunocytochemical detection of this protein on cell membrane. However, in specific cases, CSF β2m measurement and CSF/serum β2m ratio were helpful in diagnosing and monitoring isolated CNS disease. Such findings suggest that CSF-β2m assay may be a useful tool in the management of CNS involvement in the course of ALL in only selected patients, as several factors can modify the outcome.

Original languageEnglish
Pages (from-to)213-218
Number of pages6
JournalAmerican Journal of Hematology
Volume28
Issue number4
Publication statusPublished - 1988

Fingerprint

beta 2-Microglobulin
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cerebrospinal Fluid
Central Nervous System
Central Nervous System Diseases
Membrane Proteins
Phenotype
Control Groups
Serum
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Significance and limits of cerebrospinal fluid beta-2-microglobulin measurement in course of acute lymphoblastic leukemia. / Musto, P.; Tomasi, P.; Cascavilla, N.; Ladogana, S.; La Sala, A.; Melillo, L.; Nobile, M.; Castoldi, G.; Carotenuto, M.

In: American Journal of Hematology, Vol. 28, No. 4, 1988, p. 213-218.

Research output: Contribution to journalArticle

Musto, P, Tomasi, P, Cascavilla, N, Ladogana, S, La Sala, A, Melillo, L, Nobile, M, Castoldi, G & Carotenuto, M 1988, 'Significance and limits of cerebrospinal fluid beta-2-microglobulin measurement in course of acute lymphoblastic leukemia', American Journal of Hematology, vol. 28, no. 4, pp. 213-218.
Musto, P. ; Tomasi, P. ; Cascavilla, N. ; Ladogana, S. ; La Sala, A. ; Melillo, L. ; Nobile, M. ; Castoldi, G. ; Carotenuto, M. / Significance and limits of cerebrospinal fluid beta-2-microglobulin measurement in course of acute lymphoblastic leukemia. In: American Journal of Hematology. 1988 ; Vol. 28, No. 4. pp. 213-218.
@article{156502075306498cbc91402bf620520a,
title = "Significance and limits of cerebrospinal fluid beta-2-microglobulin measurement in course of acute lymphoblastic leukemia",
abstract = "Cerebrospinal fluid beta-2-microglobulin (CSF-β2m) was measured longitudinally in 48 patients affected by acute lymphoblastic leukemia (ALL). Thirteen developed a central nervous system (CNS) involvement during the course of the disease; although moderately higher mean CSF-β2m levels were found in these subjects, no significant statistical differences were observed in comparison with patients without this complication and compared with the control group. No correlations were found between β2m and other biochemical parameters in CSF. Furthermore, CSF-β2m levels appeared to be influenced by previous combined chemoradiotherapeutic treatment for CNS prophylaxis, presence of meningeal non-neoplastic infiltrates, patients' ages, amount of CSF blasts, and their immunological phenotype. In particular, only clearly B-committed leukemic cells, when tested, showed a strong surface expression of β2m, as demonstrated by immunocytochemical detection of this protein on cell membrane. However, in specific cases, CSF β2m measurement and CSF/serum β2m ratio were helpful in diagnosing and monitoring isolated CNS disease. Such findings suggest that CSF-β2m assay may be a useful tool in the management of CNS involvement in the course of ALL in only selected patients, as several factors can modify the outcome.",
author = "P. Musto and P. Tomasi and N. Cascavilla and S. Ladogana and {La Sala}, A. and L. Melillo and M. Nobile and G. Castoldi and M. Carotenuto",
year = "1988",
language = "English",
volume = "28",
pages = "213--218",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Significance and limits of cerebrospinal fluid beta-2-microglobulin measurement in course of acute lymphoblastic leukemia

AU - Musto, P.

AU - Tomasi, P.

AU - Cascavilla, N.

AU - Ladogana, S.

AU - La Sala, A.

AU - Melillo, L.

AU - Nobile, M.

AU - Castoldi, G.

AU - Carotenuto, M.

PY - 1988

Y1 - 1988

N2 - Cerebrospinal fluid beta-2-microglobulin (CSF-β2m) was measured longitudinally in 48 patients affected by acute lymphoblastic leukemia (ALL). Thirteen developed a central nervous system (CNS) involvement during the course of the disease; although moderately higher mean CSF-β2m levels were found in these subjects, no significant statistical differences were observed in comparison with patients without this complication and compared with the control group. No correlations were found between β2m and other biochemical parameters in CSF. Furthermore, CSF-β2m levels appeared to be influenced by previous combined chemoradiotherapeutic treatment for CNS prophylaxis, presence of meningeal non-neoplastic infiltrates, patients' ages, amount of CSF blasts, and their immunological phenotype. In particular, only clearly B-committed leukemic cells, when tested, showed a strong surface expression of β2m, as demonstrated by immunocytochemical detection of this protein on cell membrane. However, in specific cases, CSF β2m measurement and CSF/serum β2m ratio were helpful in diagnosing and monitoring isolated CNS disease. Such findings suggest that CSF-β2m assay may be a useful tool in the management of CNS involvement in the course of ALL in only selected patients, as several factors can modify the outcome.

AB - Cerebrospinal fluid beta-2-microglobulin (CSF-β2m) was measured longitudinally in 48 patients affected by acute lymphoblastic leukemia (ALL). Thirteen developed a central nervous system (CNS) involvement during the course of the disease; although moderately higher mean CSF-β2m levels were found in these subjects, no significant statistical differences were observed in comparison with patients without this complication and compared with the control group. No correlations were found between β2m and other biochemical parameters in CSF. Furthermore, CSF-β2m levels appeared to be influenced by previous combined chemoradiotherapeutic treatment for CNS prophylaxis, presence of meningeal non-neoplastic infiltrates, patients' ages, amount of CSF blasts, and their immunological phenotype. In particular, only clearly B-committed leukemic cells, when tested, showed a strong surface expression of β2m, as demonstrated by immunocytochemical detection of this protein on cell membrane. However, in specific cases, CSF β2m measurement and CSF/serum β2m ratio were helpful in diagnosing and monitoring isolated CNS disease. Such findings suggest that CSF-β2m assay may be a useful tool in the management of CNS involvement in the course of ALL in only selected patients, as several factors can modify the outcome.

UR - http://www.scopus.com/inward/record.url?scp=0023729990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023729990&partnerID=8YFLogxK

M3 - Article

C2 - 3046340

AN - SCOPUS:0023729990

VL - 28

SP - 213

EP - 218

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -